Answers are grounded in this paper and cite their sources.
Background/Objectives: Existing PCOS reviews largely catalogue natural products and reported molecular pathways. This structured critical review asks a different translational question: which constituents from weed, ruderal and invasive taxa remain credible candidates when target engagement, pharmacological direction, realistic exposure and safety are considered together. Methods: PubMed/MEDLINE, Web of Science Core Collection and CAB Abstracts were searched from inception to 2 September 2026, with CABI resources used to verify weed status. Eligible pharmacological, pharmacokinetic and toxicological evidence was critically appraised using a T1–T4 mechanistic evidence hierarchy and evaluated for exposure plausibility, methodological quality and citation integrity. Results: No positive mechanistic claim reached T3 or T4. Urtica dioica L. lignans demonstrably displace dihydrotestosterone from SHBG in vitro, but the predicted consequence for free androgen exposure in vivo remains untested; flavonoid aromatase effects are assay- and context-dependent; and several widely cited systemic mechanisms are not supported by current exposure data. Silybin exposure supports a narrower liver-directed hypothesis, whereas non-absorbed inulin-type fructans provide a luminal gut-axis case in which systemic exposure is not required. Mentha spicata L. provides a reproducible human endocrine signal but no defined active constituent or molecular target. Conclusions: The principal barrier to clinical translation is not a shortage of activity signals but the absence of demonstrated in vivo target engagement, target-site pharmacokinetics and reproductive-safety qualification. No candidate currently clears all five gates. Silybum marianum flavonolignans and Cichorium intybus inulin-type fructans are therefore only provisionally prioritized for node-specific nonclinical development, while M. spicata is a mechanism-resolution research signal rather than a pharmacological lead. The framework prioritizes the experiments needed to establish development readiness; it does not infer PCOS-specific efficacy from the existing evidence.
No takes yet. Share an insight, caveat, or question.
Chaitanya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: